利用III型干扰素反应来提高化疗的安全性和疗效
Scott G Tilden1, Madison H Ricco1, Emily A Hemann2
1University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO.
概括
第三类干扰素 (IFN-λ) 预治疗增强了纳米医药瘤积累和疗效. 这种方法通过在临床前模型中增加生存时间来改善抗癌治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
- 在瘤学瘤学.
背景情况:
- 对纳米药物的免疫反应可能会对患者的治疗结果和治疗效果产生负面影响.
- 之前已经表明,III型干扰素 (IFN-λ) 对与核酸复合的脂质纳米粒子 (脂质复合物) 的反应会影响纳米药物分布.
研究的目的:
- 为了识别产生IFN-λ的细胞类型,以响应脂质复杂,并了解IFN-λ的传播机制.
- 评估IFN-λ预处理对化疗小分子积累的影响.
- 确定IFN-λ预治疗的最佳给药途径,并评估其在小鼠瘤模型中的有效性.
主要方法:
- 研究了 lipoplex 暴露后的细胞特异 IFN-λ 生产.
- 在IFN-λ预处理后对多克索鲁比辛积累的评估变化.
- 对IFN-λ预处理的不同给药途径进行比较.
- 评估了IFN-λ预治疗对CT26瘤携带的小鼠模型中Doxil®治疗的生存的影响.
主要成果:
- 鉴定了特定的细胞类型,负责IFN-λ的产生,以应对脂质复杂.
- 证明IFN-λ预处理改变了化疗小分子如多克索鲁比辛的生物分布.
- 发现皮下注射IFN-λ是最有效的途径.
- 在接受Doxil®治疗的小鼠中,IFN-λ预治疗显著增加了生存时间.
结论:
- IFN-λ预治疗是增强纳米医药瘤向和有效性的有希望的策略.
- 这种方法有可能改善当前的抗癌纳米药物治疗方案.
- 这些发现支持基于IFN-λ的癌症治疗策略的快速临床转化.
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K


